$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa

$zvsa Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011073 Filed on March 25, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.314M	$1.519M	$11.20M
YoY Change	-34.64%	-56.6%	39.86%
% of Gross Profit
Research & Development	$512.9K	$257.1K	$3.208M
YoY Change	-51.42%	-35.71%	-44.79%
% of Gross Profit
Depreciation & Amortization	$2.600K	$2.600K	$10.40K
YoY Change	0.0%	388.72%	4.0%
% of Gross Profit
Operating Expenses	$2.827M	$1.776M	$107.8M
YoY Change	-38.45%	116.59%	679.13%
Operating Profit	-$2.827M		-$107.8M
YoY Change	-38.45%
Interest Expense	-$100.00	-$100.00	$460.00
YoY Change		-99.96%	-100.04%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.827M	-$13.93M	-$107.8M
YoY Change	-38.42%	157.1%	624.64%
Income Tax		-$596.1K	-$9.456M
% Of Pretax Income
Net Earnings	-$2.800M	-$13.34M	-$98.30M
YoY Change	-20.0%	17680.4%	307.2%
Net Earnings / Revenue
Basic Earnings Per Share	-$4.53		-$109.00
Diluted Earnings Per Share	-$4.53	-$5.96	-$109.00
COMMON SHARES
Basic Shares Outstanding	7.595M shares	43.52M shares	975.0K shares
Diluted Shares Outstanding	623.6K shares		975.0K shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.034M	$3.138M	$3.138M
YoY Change	56.43%	-46.82%	-46.82%
Cash & Equivalents	$2.034M	$3.138M
Short-Term Investments
Other Short-Term Assets	$866.5K	$215.5K	$215.5K
YoY Change	-42.23%	-46.14%	-46.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$2.900M	$3.353M	$3.353M
YoY Change	2.31%	-47.3%	-47.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.333K	$6.933K	$14.77K
YoY Change	-70.59%	-60.0%	-85.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$18.65M	$18.65M	$98.48K
YoY Change	-81.37%	-81.37%
Total Long-Term Assets	$18.75M	$18.76M	$18.76M
YoY Change	-83.28%	-83.27%	-83.26%
TOTAL ASSETS
Total Short-Term Assets	$2.900M	$3.353M	$3.353M
Total Long-Term Assets	$18.75M	$18.76M	$18.76M
Total Assets	$21.65M	$22.11M	$22.11M
YoY Change	-81.17%	-81.34%	-81.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.128M	$8.432M	$8.432M
YoY Change	27.37%	39.93%	40.53%
Accrued Expenses	$1.455M	$1.755M	$1.763M
YoY Change	-31.14%	-14.56%	-16.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.583M	$10.19M	$10.19M
YoY Change	11.71%	24.51%	24.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.583M	$10.19M	$10.19M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$10.43M	$11.04M	$11.04M
YoY Change	-41.6%	-40.36%	-40.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$106.0M	-$103.2M
YoY Change	1147.06%	1997.45%
Common Stock	$83.00	$405.00
YoY Change	-91.0%	-55.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$7.168K	$7.168K
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.22M	$11.07M	$11.07M
YoY Change
Total Liabilities & Shareholders Equity	$21.65M	$22.11M	$22.11M
YoY Change	-81.17%	-81.34%	-81.34%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.800M	-$13.34M	-$98.30M
YoY Change	-20.0%	17680.4%	307.2%
Depreciation, Depletion And Amortization	$2.600K	$2.600K	$10.40K
YoY Change	0.0%	388.72%	4.0%
Cash From Operating Activities	-$3.800M	-$2.787M	-$8.721M
YoY Change	-17.39%	-17.87%	78.34%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.673M	4.346M	$5.956M
YoY Change	-7807.5%		218.52%
NET CHANGE
Cash From Operating Activities	-$3.800M	-2.787M	-$8.721M
Cash From Investing Activities
Cash From Financing Activities	$2.673M	4.346M	$5.956M
Net Change In Cash	-$1.104M	1.559M	-$2.765M
YoY Change	-76.12%	-145.93%	-8.46%
FREE CASH FLOW
Cash From Operating Activities	-$3.800M	-$2.787M	-$8.721M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001859007
CY2023Q4	ZVSA	Vendor Deposit Current VendorDepositCurrent		usd
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022Q4	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2022Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2023	ZVSA	Round Up Share Adjustment Due To Reverse Split RoundUpShareAdjustmentDueToReverseSplit		usd
CY2022Q4	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2022Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022Q4	ZVSA	Shares Issued As Consideration For Extension Of Lockup Period SharesIssuedAsConsiderationForExtensionOfLockupPeriod		usd
	ZVSA	Shares Issued As Consideration For Extension Of Lockup Period SharesIssuedAsConsiderationForExtensionOfLockupPeriod		usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits		usd
CY2022Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022Q4	ZVSA	Redemption Of Series Preferred Stock RedemptionOfSeriesPreferredStock		usd
	ZVSA	Redemption Of Series Preferred Stock RedemptionOfSeriesPreferredStock		usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022Q4	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity		usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity		usd
CY2022Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022Q4	ZVSA	Warrant Inducement Offer Exercise Proceeds WarrantInducementOfferExerciseProceeds		usd
	ZVSA	Warrant Inducement Offer Exercise Proceeds WarrantInducementOfferExerciseProceeds		usd
CY2022Q4	ZVSA	Payments Of Preferred Stock Issuance Costs PaymentsOfPreferredStockIssuanceCosts		usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023	ZVSA	Conversion Of Convertible Notes Payable And Accrued Interest Into Preferred Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoPreferredStock		usd
CY2022Q4	ZVSA	Conversion Of Convertible Notes Payable And Accrued Interest Into Preferred Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoPreferredStock		usd
CY2023	ZVSA	Conversion Of Convertible Notes Payable And Accrued Interest Into Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoCommonStock		usd
CY2022Q4	ZVSA	Conversion Of Convertible Notes Payable And Accrued Interest Into Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoCommonStock		usd
CY2022Q4	ZVSA	Reclassification Of Formerly Redeemable Common Stock ReclassificationOfFormerlyRedeemableCommonStock		usd
	ZVSA	Reclassification Of Formerly Redeemable Common Stock ReclassificationOfFormerlyRedeemableCommonStock		usd
CY2023	ZVSA	Recognition Of Rou Asset And Lease Liability RecognitionOfRouAssetAndLeaseLiability		usd
CY2022Q4	ZVSA	Recognition Of Rou Asset And Lease Liability RecognitionOfRouAssetAndLeaseLiability		usd
CY2022Q4	ZVSA	Warant Modification Incremental Value WarantModificationIncrementalValue		usd
	ZVSA	Warant Modification Incremental Value WarantModificationIncrementalValue		usd
CY2022Q4	ZVSA	Warrant Inducement Offer Incremental Value WarrantInducementOfferIncrementalValue		usd
	ZVSA	Warrant Inducement Offer Incremental Value WarrantInducementOfferIncrementalValue		usd
CY2023Q4	ZVSA	Note Payable NotePayable		usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent		usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits		usd
CY2022Q4	ZVSA	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		usd
CY2022Q4	ZVSA	Deferred Tax Liabilities Rightofuse Asset DeferredTaxLiabilitiesRightofuseAsset		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts		usd
CY2022Q4	ZVSA	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q4	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q4	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Warrants Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsNonOptionsOutstandingIntrinsicValue		usd
CY2023Q4	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableIntrinsicValue1		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	5600000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7594863	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Orlando, Florida
CY2023Q4	us-gaap	Cash Cash	3137674	usd
CY2022Q4	us-gaap	Cash Cash	5902199	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	215459	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	225347	usd
CY2022Q4	ZVSA	Vendor Deposit Current VendorDepositCurrent	235000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3353133	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6362546	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6933	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17333	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18647903	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	100086329	usd
CY2022Q4	us-gaap	Goodwill Goodwill	11895033	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	98476	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	46659	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7839	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	98371	usd
CY2023Q4	us-gaap	Assets Assets	22114284	usd
CY2022Q4	us-gaap	Assets Assets	118506271	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8431583	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6025645	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1754533	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2053559	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8656	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108756	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10194772	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8187960	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	844914	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10323983	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11039686	usd
CY2022Q4	us-gaap	Liabilities Liabilities	18511943	usd
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	1880	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	331331	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4052119	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	257604	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4052057	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	257604	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	405	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	26	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	114300484	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104584147	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103219124	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4921178	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	62	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	7168	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	11074598	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99662997	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22114284	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118506271	usd
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3207573	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	399894	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5407859	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11213201	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	420174	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7605205	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	81438426	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11895033	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	107754233	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	820068	usd
	us-gaap	Operating Expenses OperatingExpenses	13013064	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-107754233	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-820068	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13013064	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	457	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-427542	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-607001	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107753776	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-820068	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14047607	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9455830	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-745050	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-98297946	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-75018	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14047607	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	7948209	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	10015837	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-106246155	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-75018	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24063444	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.99
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.99
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	975035	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	975035	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	257604	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	257604	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24194270	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24194270	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99681682	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56333	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-75018	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99662997	usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	331331	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	671620	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-5500	usd
CY2023	ZVSA	Registered Offering Of Common Stock Value RegisteredOfferingOfCommonStockValue	15723908	usd
CY2023	ZVSA	Preferred Stock Redeemed Or Called During Period Value PreferredStockRedeemedOrCalledDuringPeriodValue	-10295049	usd
CY2023	ZVSA	Shares Issued As Consideration For Extension Of Lockup Period Value SharesIssuedAsConsiderationForExtensionOfLockupPeriodValue	1156778	usd
CY2023	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-7168	usd
CY2023	ZVSA	Adjustments To Additional Paid In Capital Warrant Modification AdjustmentsToAdditionalPaidInCapitalWarrantModification	181891	usd
CY2023	ZVSA	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	1126	usd
CY2023	ZVSA	Stock Issued During Period Value Warrant Inducement Offer Exercise Proceeds StockIssuedDuringPeriodValueWarrantInducementOfferExerciseProceeds	757647	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1192963	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-98297946	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	11074598	usd
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-98297946	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-75018	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14047607	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	81438426	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11895033	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1192963	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	56333	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3524801	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	671620	usd
CY2023	ZVSA	Shares Issued As Consideration For Extension Of Lockup Period SharesIssuedAsConsiderationForExtensionOfLockupPeriod	1156778	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	39492	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-607001	usd
CY2023	us-gaap	Depreciation Depreciation	10400	usd
CY2022Q4	us-gaap	Depreciation Depreciation	532	usd
	us-gaap	Depreciation Depreciation	9868	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	90532	usd
CY2022Q4	us-gaap	Other Noncash Expense OtherNoncashExpense	4443	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	79918	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-9479069	usd
CY2022Q4	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-745050	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-56547	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-36606	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-73675	usd
CY2023	ZVSA	Increase Decrease In Vendor Deposits IncreaseDecreaseInVendorDeposits	-136524	usd
CY2022Q4	ZVSA	Increase Decrease In Vendor Deposits IncreaseDecreaseInVendorDeposits	-125645	usd
	ZVSA	Increase Decrease In Vendor Deposits IncreaseDecreaseInVendorDeposits	-255627	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2405938	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2076863	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6617064	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-100100	usd
CY2022Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4786	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-86100	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	101535	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-715730	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1431620	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8720819	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3393888	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1494641	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	18114193	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2417095	usd
CY2023	ZVSA	Redemption Of Series Preferred Stock RedemptionOfSeriesPreferredStock	10695611	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1964524	usd
CY2023	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	7168	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1126	usd
CY2023	ZVSA	Warrant Inducement Offer Exercise Proceeds WarrantInducementOfferExerciseProceeds	966349	usd
CY2023	ZVSA	Payments Of Preferred Stock Issuance Costs PaymentsOfPreferredStockIssuanceCosts	5500	usd
	ZVSA	Payments Of Preferred Stock Issuance Costs PaymentsOfPreferredStockIssuanceCosts	99140	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5956294	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1865384	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2764525	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3393888	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	370743	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5902199	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	699324	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	328581	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3137674	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5902199	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	699324	usd
	ZVSA	Conversion Of Convertible Notes Payable And Accrued Interest Into Preferred Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoPreferredStock	-5658888	usd
	ZVSA	Conversion Of Convertible Notes Payable And Accrued Interest Into Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoCommonStock	-5838209	usd
CY2023	ZVSA	Reclassification Of Formerly Redeemable Common Stock ReclassificationOfFormerlyRedeemableCommonStock	-331331	usd
	ZVSA	Recognition Of Rou Asset And Lease Liability RecognitionOfRouAssetAndLeaseLiability	-182732	usd
CY2023	ZVSA	Accounts Payable For Deferred Offering Costs AccountsPayableForDeferredOfferingCosts	-44892	usd
CY2022Q4	ZVSA	Accounts Payable For Deferred Offering Costs AccountsPayableForDeferredOfferingCosts	-240691	usd
	ZVSA	Accounts Payable For Deferred Offering Costs AccountsPayableForDeferredOfferingCosts	-667224	usd
CY2023	ZVSA	Warant Modification Incremental Value WarantModificationIncrementalValue	-181891	usd
CY2023	ZVSA	Warrant Inducement Offer Incremental Value WarrantInducementOfferIncrementalValue	-134591	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a reverse stock split of its common stock at a ratio of 1-for-35 (the “Reverse Split”). Upon the effectiveness of the Reverse Split, every 35 issued shares of common stock were reclassified and combined into one share of common stock.
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zYQk87wFVtql" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_z1oLr9ZV0K15">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, goodwill impairment, in-process research and development, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	52000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45067	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34667	usd
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023	us-gaap	Depreciation Depreciation	10400	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Depreciation Depreciation	532	usd
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
	us-gaap	Depreciation Depreciation	9868	usd
CY2023	ZVSA	Entity Valution Amount EntityValutionAmount	85000000	usd
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9155869	shares
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	342620	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25006119	shares
CY2022Q4	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	191992	shares
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	176.28	pure
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	699324	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets	1093223	usd
CY2023Q2	ZVSA	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inprocess Research And Development BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInprocessResearchAndDevelopment	100086329	usd
CY2023Q2	us-gaap	Goodwill Goodwill	11895033	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	64523	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	113139108	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	10818204	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	11069033	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	21887237	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	91251871	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11900000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	81400000	usd
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.000	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.000	pure
	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.001	pure
CY2023Q4	ZVSA	Milestone Payment Liability MilestonePaymentLiability	500000	usd
CY2022Q4	ZVSA	Milestone Payment Liability MilestonePaymentLiability	1500000	usd
CY2022Q4	ZVSA	Note Payable NotePayable	-351579	usd
CY2023Q4	ZVSA	Note Net NoteNet	500000	usd
CY2022Q4	ZVSA	Note Net NoteNet	1148421	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	668803	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	584226	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	41969	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	214229	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	106683	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	536500	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	7261	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1754533	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2053559	usd
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	23240	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	23240	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-19104800	usd
CY2022Q4	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-151625	usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2191344	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4468170	usd
CY2022Q4	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-34844	usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-482283	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-23572970	usd
CY2022Q4	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-186469	usd
	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-2673627	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	14093900	usd
CY2022Q4	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-558581	usd
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2673627	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9455830	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-745050	usd
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036	pure
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036	pure
CY2023	ZVSA	Effective Income Tax Rate Reconciliation Permanent Difference Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent	-0.028	pure
CY2022Q4	ZVSA	Effective Income Tax Rate Reconciliation Permanent Difference Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent	-0.019	pure
	ZVSA	Effective Income Tax Rate Reconciliation Permanent Difference Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencePercent	-0.054	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000	pure
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.131	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.681	pure
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.190	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.088	pure
CY2022Q4	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.908	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9974075	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6671907	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6639882	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3258463	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2936945	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4084595	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2182104	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2421390	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2362939	usd
CY2023Q4	ZVSA	Deferred Tax Assets Capitalized Startup Costs DeferredTaxAssetsCapitalizedStartupCosts	1033504	usd
CY2022Q4	ZVSA	Deferred Tax Assets Capitalized Startup Costs DeferredTaxAssetsCapitalizedStartupCosts	1121802	usd
CY2022Q4	ZVSA	Deferred Tax Assets Capitalized Startup Costs DeferredTaxAssetsCapitalizedStartupCosts	565530	usd
CY2023Q4	ZVSA	Deferred Tax Assets Capitalized Licensing Costs DeferredTaxAssetsCapitalizedLicensingCosts	647489	usd
CY2022Q4	ZVSA	Deferred Tax Assets Capitalized Licensing Costs DeferredTaxAssetsCapitalizedLicensingCosts	687926	usd
CY2022Q4	ZVSA	Deferred Tax Assets Capitalized Licensing Costs DeferredTaxAssetsCapitalizedLicensingCosts	689820	usd
CY2023Q4	ZVSA	Deferred Tax Assets Capitalized Patents DeferredTaxAssetsCapitalizedPatents	351721	usd
CY2022Q4	ZVSA	Deferred Tax Assets Capitalized Patents DeferredTaxAssetsCapitalizedPatents	288123	usd
CY2022Q4	ZVSA	Deferred Tax Assets Capitalized Patents DeferredTaxAssetsCapitalizedPatents	273682	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves	134341	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves	133203	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves	238768	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	299487	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	71830	usd
CY2023Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	2857	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	2833	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	2833	usd
CY2023Q4	ZVSA	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	2151	usd
CY2022Q4	ZVSA	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	26794	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17886192	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14362753	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14858049	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14093900	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14853648	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3792292	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14362753	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4401	usd
CY2023Q4	ZVSA	Deferred Tax Liabilities Rightofuse Asset DeferredTaxLiabilitiesRightofuseAsset	1948	usd
CY2022Q4	ZVSA	Deferred Tax Liabilities Rightofuse Asset DeferredTaxLiabilitiesRightofuseAsset	24236	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	4633535	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	24658231	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1723	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4270	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4401	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4637206	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	24686737	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4401	usd
CY2023Q4	ZVSA	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	-844914	usd
CY2022Q4	ZVSA	Deferred Tax Assets Liabilities DeferredTaxAssetsLiabilities	-10323984	usd
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	40807990	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	27515427	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	32322138	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	20567703	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	27385445	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	20458902	usd
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2673627	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14853648	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-558581	usd
CY2023	ZVSA	Deferred Tax Liabilities Valuation Allowance DeferredTaxLiabilitiesValuationAllowance	14093900	usd
CY2015Q4	ZVSA	License Agreements Up Front Cash Payment LicenseAgreementsUpFrontCashPayment	200000	usd
CY2015Q4	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	21500000	usd
CY2020	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	1500000	usd
CY2021	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	500000	usd
CY2015Q4	ZVSA	Second License Agreement Milestone Value SecondLicenseAgreementMilestoneValue	2500000	usd
CY2020Q1	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	1000000	usd
CY2020Q1	ZVSA	Cash Payment Exercise Price Withheld CashPaymentExercisePriceWithheld	351579	usd
CY2019Q2	ZVSA	Aggregate Milestone Cash Payments AggregateMilestoneCashPayments	22500000	usd
CY2019Q2	ZVSA	Milestone Payment Description MilestonePaymentDescription	the first milestone payment of $200,000 is triggered by the submission of an investigational new drug application for the first indication of a therapeutic licensed product). ZyVersa is required to pay sales royalties to InflamaCORE between 5% and 10%, which expire upon the latest of: (a) expiration of the last-to-expire of a patent or (b) expiration of regulatory exclusivity, as defined in the agreement. ZyVersa is required to pay sales royalties to the University of Miami between 3% and 6%.
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023	us-gaap	Payments For Rent PaymentsForRent	154841	usd
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2022Q4	us-gaap	Payments For Rent PaymentsForRent	7795	usd
	us-gaap	Payments For Rent PaymentsForRent	148881	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	100099	usd
CY2022Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	4786	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	86100	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y29D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y29D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y29D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8703	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	48	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8656	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	111000000	shares
CY2023Q4	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	251000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	32373	usd
CY2023Q2	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	70.00
CY2023Q4	ZVSA	Satisfaction Of Liabiilites SatisfactionOfLiabiilites	5062000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1192963	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1027460	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y8M12D
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	56333	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3524801	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2957047	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y7M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	ten
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	2858	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	184426	usd
CY2023Q1	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm1	P3Y
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	73.85
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	ten
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	372	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	23770	usd
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	79.10
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	372	shares
CY2023Q1	us-gaap	Shares Issued SharesIssued	143	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	ten
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	41523	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	555004	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	499660	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	55344	usd
CY2023Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	15.25
CY2023	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	56999	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	366.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	44753	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.52
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	101752	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	220.65
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	56284	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	333.65
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	101752	shares
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	56284	shares
CY2023Q3	ZVSA	Placement Agent Fees PlacementAgentFees	57980	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	16131	usd
CY2023Q3	ZVSA	Warrant Modification Costs WarrantModificationCosts	134591	usd
CY2023Q3	ZVSA	Incremental Fair Value IncrementalFairValue	134591	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	246594	shares
CY2022Q4	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	376.11
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	8881859	shares
CY2023	ZVSA	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice	2.71
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	203463	shares
CY2023	ZVSA	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercised In Period Weighted Average Exercised Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisedPrice	4.75
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	9447	shares
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice	32.47
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOld	-24672	shares
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldInPeriodWeightedAverageExercisePrice	402.50
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNew	141868	shares
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewInPeriodWeightedAverageExercisePrice	70.00
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old Two ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldTwo	-39372	shares
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old In Period Weighted Average Exercise Price Old Two ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldInPeriodWeightedAverageExercisePriceOldTwo	35.00
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New Two ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewTwo	39372	shares
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New In Period Weighted Average Exercise Price New Two ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewInPeriodWeightedAverageExercisePriceNewTwo	5.78
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old Three ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldThree	-203463	shares
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old In Period Weighted Average Exercise Price Old Three ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldInPeriodWeightedAverageExercisePriceOldThree	5.78
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New Three ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewThree	203463	shares
CY2023	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New In Period Weighted Average Exercise Price New Three ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewInPeriodWeightedAverageExercisePriceNewThree	4.75
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	9032739	shares
CY2023Q4	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	12.34
CY2023	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2	P3Y2M12D
CY2023Q4	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	8827273	shares
CY2023Q4	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	12.48
CY2023	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Non Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsNonOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y3M18D
CY2023Q1	ZVSA	Percentage Of Registration Delay Payments PercentageOfRegistrationDelayPayments	0.015	pure
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.020	pure
CY2023Q4	ZVSA	Accrued Registration Delay Payments AccruedRegistrationDelayPayments	7261	usd

Files In Submission

Name	View Source	Status
0001493152-24-011073-index-headers.html	Edgar Link	pending
0001493152-24-011073-index.html	Edgar Link	pending
0001493152-24-011073.txt	Edgar Link	pending
0001493152-24-011073-xbrl.zip	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex4-8.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
form10-k_008.jpg	Edgar Link	pending
form10-k_009.jpg	Edgar Link	pending
form10-k_010.jpg	Edgar Link	pending
form10-k_011.jpg	Edgar Link	pending
form10-k_012.jpg	Edgar Link	pending
form10-k_013.jpg	Edgar Link	pending
form10-k_014.jpg	Edgar Link	pending
form10-k_015.jpg	Edgar Link	pending
form10-k_016.jpg	Edgar Link	pending
form10-k_017.jpg	Edgar Link	pending
form10-k_018.jpg	Edgar Link	pending
form10-k_019.jpg	Edgar Link	pending
form10-k_020.jpg	Edgar Link	pending
form10-k_021.jpg	Edgar Link	pending
form10-k_022.jpg	Edgar Link	pending
form10-k_023.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zvsa-20231231.xsd	Edgar Link	pending
zvsa-20231231_cal.xml	Edgar Link	unprocessable
zvsa-20231231_def.xml	Edgar Link	unprocessable
zvsa-20231231_lab.xml	Edgar Link	unprocessable
zvsa-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa

2024 Q1 Form 10-K Financial Statement

#000149315224011073 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZVSA ZyVersa Therapeutics, Inc. Stock $zvsa

2024 Q1 Form 10-K Financial Statement

#000149315224011073 Filed on March 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa